Tumor genetic testing for patient selection in phase I clinical trials: The case of PI3K inhibitors

Journal of Clinical Oncology

Volumn 30, Issue 8, 2012, Pages 765-766

  Juric, Dejan ^a   Baselga, José ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; DOXORUBICIN; EVEROLIMUS; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAPAMYCIN; TEMSIROLIMUS;

BREAST CANCER; CANCER GENETICS; DRUG RESPONSE; DRUG SENSITIVITY; EDITORIAL; GENE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; LUNG CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PI3K GENE; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84858842073     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.6390     Document Type: Editorial

References (18)

1. Haber DA, Gray NS, Baselga J: The evolving war on cancer. Cell 145:19-24, 2011
2. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002 (Pubitemid 34716871)
3. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004 (Pubitemid 38541907)
4. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
5. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
6. Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127, 2010
7. Coutre SE, Byrd JC, Furman RR, et al: Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. ASCO Meeting Abstracts 29:451s, 2011 (suppl 15; abstr 6631)
8. Von Hoff DD, LoRusso PM, Rudin CM, et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164-1172, 2009
9. Rudin CM, Hann CL, Laterra J, et al: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173-1178, 2009
10. Dias-Santagata D, Akhavanfard S, David SS, et al: Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med 2:146-158, 2010
11. Janku F, Wheler JJ, Westin SN, et al: PI3K/AKT/mTOR inhibitors in patients with breast and gynecological malignancies harboring PIK3CA mutations. J Clin Oncol 30:777-782, 2012
12. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296:1655-1657, 2002
13. Brachmann SM, Hofmann I, Schnell C, et al: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 106:22299-22304, 2009
14. O'Brien C, Wallin JJ, Sampath D, et al: Predictive biomarkers of sensitivity to the phosphatidylinositol 3- kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16:3670-3683, 2010
15. Roper J, Richardson MP, Wang WV, et al: The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 6:e25132, 2011
16. Serra V, Markman B, Scaltriti M, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68:8022-8030, 2008
17. Weigelt B, Warne PH, Downward J: PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30:3222-3233, 2011
18. Baselga J, Semiglazov V, van Dam P, et al: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630-2637, 2009